Saturday 17 October 2026
Export URGN’s income statement to Excel — free account
Urogen Pharma
URGN Healthcare Biotechnology
Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
34.56
2.05
−5.60%
Follow URGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.82 | 6.42 | 10.26 | 9.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(56.17) | (19.91) | (29.40) | (22.68) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
10.26 | 6.76 | 10.30 | 9.87 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(12.18) | (5.73) | (6.96) | (6.92) | |
EV/FCF |
(12.17) | (5.72) | (6.95) | (6.90) | |
Quick Ratio |
3.20 | 3.89 | 3.34 | 3.51 | |
Current Ratio |
3.80 | 4.69 | 4.01 | 3.99 | |
Net Debt/EBITDA |
505.33 | (2.38) | (0.20) | 0.22 | |
Debt/Assets |
75.88% | 74.71% | 62.70% | 65.99% | |
Debt/Equity |
(1.45) | (1.53) | (1.19) | (1.06) | |
Asset Turnover |
0.82 | 0.56 | 0.45 | 0.40 | |
Operating CF/Net income |
2.30 | 1.92 | 1.45 | 1.27 | |
Capex/Depreciation |
(1.15) | (0.53) | 0.00 | 0.05 | |
Interest Coverage |
0.02 | (4.84) | (5.07) | (8.12) | |
Research and Development Expense of Revenue |
23.93% | 30.61% | 37.83% | 50.97% | |
Selling, General and Administrative Expense of Revenue |
66.85% | 101.03% | 104.00% | 136.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.36% | 9.08% | 8.27% | 11.01% | |
Graham Net Nets |
(0.08) | (0.16) | (0.11) | (0.14) | |
Graham Number |
10.82 | 12.38 | 12.56 | 13.67 | |
Earnings Yield |
(5.38%) | (15.29%) | (13.66%) | (17.34%) | |
Free Cash Flow Yield |
(8.58%) | (18.40%) | (14.44%) | (14.41%) | |
Revenue per Share |
1.44 | 1.02 | 0.79 | 0.57 | |
Operating CF per Share |
(0.66) | (0.90) | (0.80) | (0.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.66) | (0.90) | (0.80) | (0.88) | |
Cash per Share |
2.17 | 2.82 | 2.53 | 2.67 | |
Shareholders Equity per Share |
(2.63) | (2.48) | (2.19) | (2.40) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.63) | (2.48) | (2.19) | (2.40) | |
Free Cash Flow |
(33.07) | (45.37) | (38.34) | (42.36) | |
Working Capital |
173.51 | 186.83 | 139.61 | 126.30 | |
Capital Expenditures |
(0.06) | (0.05) | (0.02) | (0.09) | |
Net Current Asset Value |
(149.56) | (140.48) | (119.90) | (131.91) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
54.20 | 37.53 | 26.69 | 21.25 | |
Average Payables |
35.45 | 32.83 | 27.57 | 22.93 | |
Average Inventory |
15.86 | 14.26 | 12.85 | 7.97 | |
Average Assets |
230.65 | 250.65 | 243.08 | 243.49 | |
Average Common Equity |
(112.89) | (85.36) | (57.14) | (44.95) |
Columns are period end dates